Latent Labs: Revolutionizing AI MedTech with £40m Funding
Deal News | Feb 13, 2025 | Business Cloud
Latent Labs, an AI MedTech startup headquartered in London and San Francisco, has emerged from stealth mode after securing £40 million in Series A funding. The company, which focuses on making biology programmable through AI foundation models, was founded by Dr. Simon Kohl, a former senior research scientist at DeepMind. The funding round was co-led by Radical Ventures and Sofinnova Partners, with participation from Flying Fish, Isomer, and existing investors 8VC, Kindred Capital, and Pillar VC. Latent Labs aims to empower researchers to create new therapeutic molecules computationally. Their platform promises to expedite drug development timelines and improve success rates, positioning the company at the forefront of computational biology. Notable angel investors include Google's Jeff Dean and Cohere's Aidan Gomez. The company has attracted a talented team from renowned organizations such as DeepMind and Microsoft.
Sectors
- MedTech
- Artificial Intelligence
- Biotechnology
Geography
- United Kingdom – Latent Labs is headquartered in London, establishing its presence and operational base within the UK.
- United States – The company is also headquartered in San Francisco, indicating its operational activities and market interest in the US.
Industry
- MedTech – The article discusses Latent Labs, a company at the intersection of medical technology and artificial intelligence, which is revolutionizing drug design through advanced computational biology.
- Artificial Intelligence – Latent Labs is utilizing AI foundation models to make biology programmable and to design new therapeutic molecules, highlighting significant advancements in AI applications within the biotech field.
- Biotechnology – The company's focus on creating programmable biology through AI and developing new therapeutic molecules categorizes it within the biotechnology industry.
Financials
- £40 million – Series A funding round secured by Latent Labs.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Latent Labs | Target Company | Company | An AI MedTech company focused on making biology programmable to advance drug design. |
| Dr. Simon Kohl | Founder | Person | Co-founder of Latent Labs and former DeepMind scientist with expertise in protein design. |
| Radical Ventures | Bidding Company / Fund Provider | Company | One of the co-leaders of the Series A funding round for Latent Labs. |
| Sofinnova Partners | Bidding Company / Fund Provider | Company | Co-leader of the Series A funding round for Latent Labs. |
| Flying Fish | Investor | Company | A participant in the Series A funding for Latent Labs. |
| Isomer | Investor | Company | A participant in the Series A funding round for Latent Labs. |
| 8VC | Investor | Company | An existing investor participating in the Series A funding for Latent Labs. |
| Kindred Capital | Investor | Company | An existing investor participating in the Series A funding for Latent Labs. |
| Pillar VC | Investor | Company | An existing investor participating in the Series A funding for Latent Labs. |
| Jeff Dean | Angel Investor | Person | Chief scientist at Google and notable angel investor in Latent Labs. |
| Aidan Gomez | Angel Investor | Person | Inventor of the Transformer architecture and founder of Cohere, angel investor in Latent Labs. |
| Mati Staniszewski | Angel Investor | Person | Founder of ElevenLabs and notable angel investor in Latent Labs. |